secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0000950170-25-078428
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen discontinues DMD program after PGN-EDO51 misses dystrophin target; shifts focus to DM1
--------------------------------------------------------------------------------

- 10 mg/kg PGN-EDO51: total dystrophin only 0.59% of normal (mean increase 0.36%); exon skipping +3.5%.
- Company voluntarily discontinuing PGN-EDO51 and winding down all DMD research & development.
- DM1 program prioritized; FREEDOM-DM1 15 mg/kg data expected H2 2025, FREEDOM2-DM1 5 mg/kg data Q1 2026.
- PGN-EDO51 safety favorable; all treatment-related AEs mild, no serious adverse events.
- Prior DM1 data (10 mg/kg single dose) showed 29% mean mis-splicing correction at safety update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/0000950170-25-078428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025078428/pepg-20250528.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-078428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer